- Home
- KZIA vs AIMD Comparison
KZIA vs AIMD Comparison
Compare KZIA & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- AIMD
- Stock Information
- Founded
- KZIA 1994
- AIMD 1984
- Country
- KZIA Australia
- AIMD United States
- Employees
- KZIA N/A
- AIMD N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- AIMD Health Care
- Exchange
- KZIA Nasdaq
- AIMD Nasdaq
- Market Cap
- KZIA 7.8M
- AIMD 8.5M
- IPO Year
- KZIA 1999
- AIMD N/A
- Fundamental
- Price
- KZIA $1.29
- AIMD $0.62
- Analyst Decision
- KZIA Strong Buy
- AIMD
- Analyst Count
- KZIA 2
- AIMD 0
- Target Price
- KZIA $11.50
- AIMD N/A
- AVG Volume (30 Days)
- KZIA 5.5M
- AIMD 1.3M
- Earning Date
- KZIA 03-26-2025
- AIMD 03-07-2025
- Dividend Yield
- KZIA N/A
- AIMD N/A
- EPS Growth
- KZIA N/A
- AIMD N/A
- EPS
- KZIA N/A
- AIMD N/A
- Revenue
- KZIA $1,655,324.00
- AIMD $40,633.00
- Revenue This Year
- KZIA $806.89
- AIMD N/A
- Revenue Next Year
- KZIA N/A
- AIMD N/A
- P/E Ratio
- KZIA N/A
- AIMD N/A
- Revenue Growth
- KZIA 248000.00
- AIMD N/A
- 52 Week Low
- KZIA $1.25
- AIMD $0.40
- 52 Week High
- KZIA $15.80
- AIMD $3.10
- Technical
- Relative Strength Index (RSI)
- KZIA 39.50
- AIMD 48.56
- Support Level
- KZIA $1.31
- AIMD $0.57
- Resistance Level
- KZIA $2.64
- AIMD $0.87
- Average True Range (ATR)
- KZIA 0.24
- AIMD 0.09
- MACD
- KZIA 0.09
- AIMD -0.02
- Stochastic Oscillator
- KZIA 14.29
- AIMD 17.45
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.